TransMedics Q2 FY26 GAAP net income drops 58% to USD 14.7 million; revenue rises 21% to USD 189.9 million
TMDX•Second-quarter results
TransMedics posted Q2 2026 revenue of USD 189.9 million, up 21% from a year earlier.
GAAP net income fell 58% to USD 14.7 million, with diluted EPS down 55% to USD 0.41.
GAAP operating income dropped 35% to USD 23.7 million, while gross margin narrowed 1 percentage point to 60%.
Strategic investment and guidance
The company completed a strategic investment in Germany-based PAD Aviation on July 1 to build an organ-transplant air logistics network across Europe.
TransMedics also raised the low end of full-year 2026 revenue guidance, excluding PAD Aviation, to USD 737 million-USD 757 million.
